Cortical Differentiation of Human Pluripotent Cells for In Vitro Modeling of Alzheimer’s Disease

  • Nathalie G. Saurat
  • Frederick J. LiveseyEmail author
  • Steven Moore
Part of the Methods in Molecular Biology book series (MIMB, volume 1303)


Stem cell models of Alzheimer’s disease provide an opportunity to study the mechanisms underlying disease pathology at a resolution that is not possible in animal models. Furthermore, the ability to reprogram patient somatic cells to a pluripotent state ensures that the disease can be investigated in the correct genetic context. Here, we describe the directed differentiation of human pluripotent cells to cortical progenitors by recapitulating key developmental signaling events in vitro. Over a timeframe that mirrors human development, these progenitors give rise to functional lower and upper layer neurons. We also describe biochemical and imaging based methods to analyse key APP and Tau phenotypes in neurons generated from pluripotent stem cells from individuals with either monogenic familial Alzheimer’s disease or Down’s syndrome.

Key words

Disease modeling Alzheimer’s disease Stem cell APP Abeta peptides Tau Cortical differentiation Neurodegeneration Down’s syndrome 



Work in the lab of FJL is supported by the Wellcome Trust, Alzheimer’s Research UK, the Medical Research Council and the EU Innovative Medicines Initiative StemBANCC. NS is supported by the Woolf Fisher Trust. FJL is a Wellcome Trust Senior Investigator.


  1. 1.
    Shi Y, Kirwan P, Smith J et al (2012) Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci 15:477–486, S1PubMedCrossRefGoogle Scholar
  2. 2.
    Maroof AM, Keros S, Tyson JA et al (2013) Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell 12:559–572PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Nicholas CR, Chen J, Tang Y et al (2013) Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 12:573–586PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Israel MA, Yuan SH, Bardy C et al (2012) Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 482:216–220PubMedCentralPubMedGoogle Scholar
  5. 5.
    Shi Y, Kirwan P, Smith J et al (2013) A human stem cell model of early Alzheimer’s disease pathology in Down syndrome. Sci Transl Med 4:124ra29Google Scholar
  6. 6.
    Qiang L, Fujita R, Yamashita T et al (2011) Directed conversion of Alzheimer’s disease patient skin fibroblasts into functional neurons. Cell 146:359–371PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676PubMedCrossRefGoogle Scholar
  8. 8.
    Park IH, Arora N, Huo H et al (2008) Disease-specific induced pluripotent stem cells. Cell 134:877–886PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Yagi T, Ito D, Okada Y, Akamatsu W et al (2011) Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet 20:4530–4539PubMedCrossRefGoogle Scholar
  10. 10.
    Kondo T, Asai M, Tsukita K et al (2013) Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12:487–496PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Nathalie G. Saurat
    • 1
    • 2
    • 3
  • Frederick J. Livesey
    • 1
    • 2
    • 3
    Email author
  • Steven Moore
    • 1
    • 2
    • 3
  1. 1.Cambridge Stem Cell InstituteUniversity of CambridgeCambridgeUK
  2. 2.Department of BiochemistryUniversity of CambridgeCambridgeUK
  3. 3.Gurdon InstituteUniversity of CambridgeCambridgeUK

Personalised recommendations